by David Eyre | May 25, 2023 | EPO
In laboratory practice the production of new antibodies is now often considered routine with a desired epitope synthesised and used to raise antibodies to that specific sequence. Accordingly under European practice the EPO views generating antibodies against any known...
by David Eyre | Feb 28, 2023 | UK
In this decision the Hearing Officer noted that a marketing authorisation is focused on what a product is rather than what it does. Consequently, a change in how the authorised product is used does not alter the basis of the original marketing authorisation....
by Sean HutchinsonEddie Bishop | Feb 8, 2022 | EPO
Background In our previous article, we discussed the expected referral to the Enlarged Board of Appeal in case T 116/18, wherein the Board of Appeal decided greater clarity was required concerning the use of post-published data when considering inventive step. The...
by David Eyre | May 1, 2021 | US & International
Up until now, there has been an international system for disclosing nucleic acid and proteins sequences in a format that can be used by patent offices for searching and examination of patent applications. This system is administered by the World Intellectual Property...
by Sean Hughes | Feb 1, 2021 | US & International
Key Revisions to the Chinese Guidelines for Patent Examination Supplementary Data Historically, in China, the rules on submitting supplementary data in favour of sufficiency and/or inventive step have been very strict throughout patent prosecution. This was bad news...
Recent Comments